EP2038653A4 - Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use - Google Patents

Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use

Info

Publication number
EP2038653A4
EP2038653A4 EP07809392A EP07809392A EP2038653A4 EP 2038653 A4 EP2038653 A4 EP 2038653A4 EP 07809392 A EP07809392 A EP 07809392A EP 07809392 A EP07809392 A EP 07809392A EP 2038653 A4 EP2038653 A4 EP 2038653A4
Authority
EP
European Patent Office
Prior art keywords
inhibitors
substrates
methods
cleaving enzyme
antiplasmin cleaving
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07809392A
Other languages
German (de)
French (fr)
Other versions
EP2038653A2 (en
Inventor
Patrick A Mckee
Kyung N Lee
Kenneth W Jackson
Victoria J Christiansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP2038653A2 publication Critical patent/EP2038653A2/en
Publication of EP2038653A4 publication Critical patent/EP2038653A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
EP07809392A 2006-06-07 2007-06-06 Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use Withdrawn EP2038653A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81156806P 2006-06-07 2006-06-07
US83636506P 2006-08-08 2006-08-08
PCT/US2007/013480 WO2007146104A2 (en) 2006-06-07 2007-06-06 Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use

Publications (2)

Publication Number Publication Date
EP2038653A2 EP2038653A2 (en) 2009-03-25
EP2038653A4 true EP2038653A4 (en) 2010-04-21

Family

ID=38832396

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07809392A Withdrawn EP2038653A4 (en) 2006-06-07 2007-06-06 Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use

Country Status (6)

Country Link
EP (1) EP2038653A4 (en)
JP (1) JP2009539853A (en)
AU (1) AU2007258495A1 (en)
CA (1) CA2658331A1 (en)
MX (1) MX2008015649A (en)
WO (1) WO2007146104A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933201B2 (en) 2006-06-07 2015-01-13 The Board Of Regents Of The University Of Oklahoma Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use
EP3555627B1 (en) 2016-12-14 2023-11-22 Purdue Research Foundation Fibroblast activation protein (fap)-targeted imaging and therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072240A2 (en) * 2003-02-07 2004-08-26 Mckee Patrick A Antiplasmin cleaving enzyme

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072240A2 (en) * 2003-02-07 2004-08-26 Mckee Patrick A Antiplasmin cleaving enzyme

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JACKSON ET AL.: "Determination of antiplasmin cleaving enzyme substrate specificity and inhibitor development by peptide library analyzes", FASEB JOURNAL; EXPERIMENTAL BIOLOGY 2005 MEETING/35TH INTERNATIONAL CONGRESS OF PHYSIOLOGICAL SCIENCES, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, US; SAN DIEGO, CA, USA, vol. 19, no. 4, Suppl. S, Part 1, 4 March 2006 (2006-03-04), pages A864, XP008095875, ISSN: 0892-6638 *
LEE KYUNG N ET AL: "Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 107, no. 4, 1 February 2006 (2006-02-01), pages 1397 - 1404, XP002394322, ISSN: 0006-4971 *
LEE KYUNG N ET AL: "Using substrate specificity of antiplasmin-cleaving enzyme for fibroblast activation protein inhibitor design.", BIOCHEMISTRY 16 JUN 2009, vol. 48, no. 23, 16 June 2009 (2009-06-16), pages 5149 - 5158, XP002548109, ISSN: 1520-4995 *
OLESEN K ET AL: "Extended Subsite Characterization of Carboxypeptidase Y Using Substrates Based on Intramolecularly Quenched Fluorescence", PROTEIN AND PEPTIDE LETTERS, BENTHAM SCIENCE PUBLISHERS, SCHIPHOL, NL, vol. 3, no. 2, 1 January 1996 (1996-01-01), pages 67 - 74, XP009123391, ISSN: 0929-8665 *
RAMANUJAM P ET AL: "Novel peptides that inhibit the propagation of Newcastle disease virus.", ARCHIVES OF VIROLOGY MAY 2002, vol. 147, no. 5, May 2002 (2002-05-01), pages 981 - 993, XP009123371, ISSN: 0304-8608 *

Also Published As

Publication number Publication date
EP2038653A2 (en) 2009-03-25
MX2008015649A (en) 2009-03-25
CA2658331A1 (en) 2007-12-21
WO2007146104A2 (en) 2007-12-21
WO2007146104A3 (en) 2008-10-16
AU2007258495A1 (en) 2007-12-21
JP2009539853A (en) 2009-11-19

Similar Documents

Publication Publication Date Title
IL232786A0 (en) Inhibitors of e1 activating enzyme
PL1848718T3 (en) Inhibitors of e1 activating enzymes
AP2812A (en) Modified dicamba monooxygenase enzyme and methods of its use
EP2019679A4 (en) Glucose transport inhibitors and methods of use
GB0619753D0 (en) Enzyme inhibitors
TWI372796B (en) Sapphire substrates and methods of making same
TWI350784B (en) Sapphire substrates and methods of making same
IL197684A0 (en) Stem cell culture medium and methods of use thereof
EP1931205A4 (en) Transglutaminase inhibitors and methods of use thereof
EP2029762A4 (en) Enzyme compositions for the improved enzymatic hydrolysis of cellulose and methods of using same
HK1129298A1 (en) Dihydrodiazepines useful as inhibitors of protein kinases
AU2007218334A8 (en) Methods of treating diseases using inhibitors of nucleoside phosphorylases and nucleosidases
IL194699A0 (en) Tetrahydropteridines useful as inhibitors of protein kinases
EP2047864A4 (en) Use of rpn2 gene expression inhibitor
EP2086999A4 (en) Inhibitors for disrupting the interaction of ubiquitination related enzymes and uses thereof
ZA200806871B (en) Dihydrodiazepines useful as inhibitors of protein kinases
EP2087339A4 (en) Deposit removal probe and method of use
IL181819A0 (en) Enzyme inhibitors and uses thereof
EP1915443A4 (en) Immobilized enzymes and methods of using thereof
IL186120A0 (en) Inhibitors of neurotrypsin and determination thereof
GB0608844D0 (en) Enzyme inhibitors
GB0617161D0 (en) Enzyme inhibitors
EP2038653A4 (en) Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use
EP2067859A4 (en) Use of activated cytokinin-biosynthesizing enzyme gene
ZA200805723B (en) Enzyme and photobleach containing compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090107

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20100323

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100622